DOP Session 9

DOP73-81

  • 17:05-18:05 Digital Oral Presentation Session 9: Surgery and IBD
    Room: C1-M1, Hall C, Bella Center
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
      17:05-17:11 DOP73: Treatment of perianal fistulas in Crohn’s Disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): A randomised controlled trial
    See Presentation Slides here
    K. Wasmann1, E. J. de Groof2, M. Stellingwerf1, G. D'Haens3, C. Ponsioen3, K. Gecse3, M. Dijkgraaf4, W. Bemelman2, C. Buskens2
    1
    Amsterdam UMC, Department of Surgery and Gastroenterology, Amsterdam, Netherlands, 2Amsterdam UMC, Department of Surgery, Amsterdam, Netherlands, 3Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 4Amsterdam UMC, Clinical Research Unit & Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam, Netherlands
      17:11-17:17 DOP74: Efficacy of ustekinumab in perianal Crohn’s Disease: The BioLAP multicentre observational study
    See Presentation slides here
    C. Biron1, P. Seksik2, M. Nachury3, Y. Bouhnik4, A. Amiot5, S. Viennot6, M. Serrero7, M. Fumery8, M. Allez9, L. Siproudhis10, A. Buisson11, G. Pineton de Chambrun12, V. Abitbol13, S. Nancey14, L. Caillo15, L. Plastaras16, L. Armengol-Debeir17, E. Chanteloup18, M. Simon19, N. Dib20, S. Rajca21, M. Amil22, L. Peyrin-Biroulet23, L. Vuitton24
    1
    CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 5Hôpital Henri-Mondor, Gastroentérologie, Paris, France, 6CHRU Caen, Gastroentérologie, Caen, France, 7APHM Hôpital Nord, Gastroentérologie, Marseille, France, 8CHRU Amiens, Gastroentérologie, Amiens, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Rennes, Gastroentérologie, Rennes, France, 11CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 12CHRU Montpellier, Gastroentérologie, Montpellier, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 15CHU Nîmes, Gastroentérologie, Nîmes, France, 16Hôpital Pasteur, Gastroentérologie, Colmar, France, 17CHRU Rouen, Gastroentérologie, Rouen, France, 18Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 19Institut Mutualiste Monsouris, Gastroentérologie, Paris, France, 20CHRU Angers, Gastroentérologie, Angers, France, 21Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 22CHD Vendée, Gastroentérologie, La Roche-sur-Yon, France, 23CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 24CHRU Jean Minjoz, Gastroentérologie, Besançon, France
      17:17-17:23 DOP75: Surgery and hospitalisations rates in Inflammatory Bowel Disease patients in the Québec provincial database from 1996 - 2015
    C. Verdon1 J. Reinglas1, J. Coulombe2, L. Gonczi3, T. Bessissow1, W. Afif1, M. Vutcovici4, G. Wild1, E. Seidman1, A. Bitton1, P. Brassard5, 6, P. Lakatos1
    1
    McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 2Lady Davis Research Institute, Jewish General Hospital, Centre for Clinical Epidemiology, Montreal, Canada, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 4McGill University Health Centre, Division of Gastroenterology, Montreal, Canada, 5Biostatistics and Occupational Health, Department Of Epidemiology, Montreal, Canada, 6McGill University, Department of Medicine, Montreal, Canada
      17:23-17:29 DOP76: Prevalence and health-care costs of perianal fistulas in Crohn’s Disease in a nationwide cohort
    See Presentation Slides here
    A. Nordholm-Carstensen1, N. Qvist2, B. Højgaard3, C. Halling3, M. Carstensen4, N.-P. Ipland4, J. Burisch5
    1
    Zealand University Hospital, Department of Surgery, Roskilde, Denmark, 2Odense University Hospital, Department of Surgery, Odense, Denmark, 3VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark, 4Takeda Pharma A/S, Taastrup, Denmark, 5Danish Centre for eHealth & Epidemiology, Frederikssund, Denmark
      17:29-17:35 DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's Disease
    O. Knyazev, A. Kagramanova, A. Lishchinskaya, M. Zvyaglova, D. Kulakov, A. Parfenov
    Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation
      17:35-17:41 DOP78: Efficacy of vedolizumab in perianal Crohn’s Disease: The BioLAP multicentre observational study
    See Presentation Slides here
    C. Biron1, P. Seksik2, M. Nachury3, S. Nancey4, Y. Bouhnik5, M. Serrero6, L. Armengol-Debeir7, A. Buisson8, M.-L. Tran Minh9, C. Zallot10, M. Fumery11, G. Bouguen12, V. Abitbol13, S. Viennot14, E. Chanteloup15, S. Rajca16, N. Dib17, L. Peyrin-Biroulet10, L. Vuitton18
    1
    CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 5Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 6APHM Hôpital Nord, Gastroentérologie, Marseille, France, 7CHRU Rouen, Gastroentérologie, Rouen, France, 8CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 11CHRU Amiens, Gastroentérologie, Amiens, France, 12CHRU Rennes, Gastroentérologie, Rennes, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14CHRU Caen, Gastroentérologie, Caen, France, 15Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 16Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 17CHRU Angers, Gastroentérologie, Angers, France, 18CHRU Jean Minjoz, Gastroentérologie, Besançon, France
      17:41-17:47 DOP79: Effect of vedolizumab on surgical rates in IBD: Post hoc analysis from the GEMINI trials
    See Presentation Slides here
    B. G. Feagan1, B. E. Sands2, R. Lirio3, T. Lissoos3, J. Wang3, D. Feng3, K. Lasch3
    1
    Robarts Clinical Trials, Western University, London, Ontario, Canada, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, NY, United States, 3Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, United States
      17:47-17:53 DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's Disease treated with concomitant thiopurines: The POPCUR trial
    See Presentation Slides here
    A. Buisson1, D. Laharie2, S. Nancey3, X. Hébuterne4, X. Roblin5, M. Nachury6, L. Peyrin-Biroulet7, M. Fumery8, F. Goutorbe1, D. Coban1, C. Allimant1, M. Reymond1, E. Vazeille1, B. Pereira1, M. Goutte1, G. Bommelaer1
    1
    University Hospital Estaing, IBD unit, Clermont-Ferrand, France, 2CHU Bordeaux, Bordeaux, France, 3HCL Lyon-Sud, Lyon, France, 4CHU Nice, Nice, France, 5CHU Saint-Etienne, Saint-Etienne, France, 6CHU Lille, Lille, France, 7CHU Nancy, Nancy, France, 8CHU Amiens, Amiens, France
      17:53-17:59 DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s Disease
    See Presentation Slides here
    A. L. Hamilton1, P. P. De Cruz1, 2, E. K. Wright3, L. Okada4, M. Hale4, L. Mimms4, A. Jain4, M. A. Kamm1
    1The University of Melbourne and St Vincent's Hospital, Melbourne, Department of Medicine and Department of Gastroenterology, Melbourne, Australia, 2Austin Health, Department of Gastroenterology, Melbourne, Australia, 3St Vincent's Hospital, Department of Gastroenterolgy, Melbourne, Australia, 4Prometheus Laboratories Inc, San Diego, United States

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark